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In  the  oral  and  maxillofacial  region,  conditions  such  as  bone  fracture,  trauma-induced  bone  or  cartilage
defects,  and  tumor  or birth  defects  are  common,  and  it is  necessary  to elucidate  the  molecular  mecha-
nisms  that  control  the  differentiation  of  cells  to  establish  new  treatment  strategies  for  these  conditions.
Therefore,  numerous  studies  have  investigated  the  role  or involvement  of factors  that  are  thought  to be
crucial  for  differentiation  of  cells,  including  cell  cycle  factors,  transcription  factors,  and  growth  factors.
One  of these  types  of  factors,  the  cell cycle  factors,  critically  inﬂuence  the  differentiation  of  cells,  since
a  temporal  arrest  in  the  G1 phase  of  the cell  cycle  or withdrawal  from  the  cell  cycle  is  thought  to  be  a
prerequisite  for  cell  differentiation.  In  a  previous  attempt  to  identify  cell  cycle  factor(s)  controlling  the
commitment  for differentiation  of  cells,  we  discovered  that  cyclin-dependent  kinase  (Cdk)6,  one  of  the
G1 cell  cycle  factors,  is  a  critical  regulator  of the  differentiation  efﬁciency  of  osteoblasts,  osteoclasts,  and
chondrocytes.  In addition,  individual  groups  have  also  reported  the  importance  of Cdk6  in differentiation
in  other  cell  types.  Herein,  we review  the  role  of  Cdk6  in  differentiation  of cells  with  a  particular  focus
on  osteoblast,  osteoclast,  and  chondrocyte  differentiation  and  discuss  the  potential  of  Cdk6  as  a  target  of
bone  regenerative  medicine.
© 2011 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
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. Introduction
In the oral and maxillofacial region, conditions such as bone frac-
rent gold standard strategy. However, bone grafts present problems
with respect to the availability of bone graft material, difﬁculties
with the donor site etc. In order to establish new treatment strate-ure, trauma-induced bone or cartilage defects, and tumor or birth
efects such as cleft lip and palate (CLP) are common. To repair
rreversible skeletal damage or defects, bone grafts are the cur-
∗ Corresponding author. Tel.: +81 3 5800 8669; fax: +81 3 5800 6832.
E-mail  address: takato-ora@h.u-tokyo.ac.jp (T. Takato).
348-8643/$ – see front matter ©  2011 Japanese Stomatological Society. Published by Els
oi:10.1016/S1348-8643(11)00007-3gies for such conditions, one of the most important goals is to
clarify the molecular mechanisms that control the differentiation
of cells. Accordingly, numerous studies have been conducted to
investigate the role or involvement of factors which are thought
to be crucial for differentiation of cells, including cell cycle fac-
tors, transcription factors, and growth factors. Cell cycle factors
in particular are considered to critically inﬂuence the differenti-
evier Ltd. All rights reserved.
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Fig. 1. Cell cycle factors functioning in G1 phase. Cell cycle progression is controlled
by  the action of cyclins and Cdks, which phosphorylate and activate cell cycle factors
essential for the onset of the next cell cycle phase. On the other hand, cell cycle
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crrest  is thought to be controlled mainly by CKIs, which inhibit Cdks or Cdk-cyclin
omplexes.  A temporal arrest in the G1 phase or withdrawal from the cell cycle is
hought to be a prerequisite for cell differentiation.
tion of cells, since a temporal arrest in the G1 phase of the cell
ycle or withdrawal from the cell cycle is thought to be a prereq-
isite for cell differentiation [1,2]. Proliferation of eukaryotic cells
s dependent on their progression through the cell cycle. The cell
ycle is controlled by cyclins, cyclin-dependent kinases (Cdks), and
yclin-dependent kinase inhibitors (CKIs). Cyclins and Cdks acti-
ate cell cycle factors essential for the start of the next cell cycle
hase. In contrast, CKIs negatively regulate Cdks by direct bind-
ng to cyclins and Cdks [3,4]. In mammalian cells, passing through
he G1 phase and following S phase entry requires the activities of
he cyclin D-dependent kinases Cdk4 and/or Cdk6 and the cyclin
-dependent kinase Cdk2 [5]. Cdk4 and Cdk6 have 71% amino acid
dentity, are structurally homologous and share all three D-type
yclins, i.e. CyclinD1, CyclinD2, CyclinD3, as their catalytic partners
o phosphorylate pRb in vitro [6]. Consequently, Cdk4 and Cdk6 had
een considered to function redundantly in the G1 phase of the cell
ycle. CKIs have been classiﬁed into two families: the INK4 fam-
ly and Cip/Kip family. In general, the INK4 family (p16, p15, p18,
nd p19) inhibits only Cdk4 and Cdk6, whereas the Cip/Kip family
p21, p27, and p57) inhibits all the Cdks. A schematic presentation
f cell cycle regulation and differentiation is shown in Fig. 1. As
entioned above, because a temporal cell cycle arrest in the G1
hase or withdrawal from the cell cycle is thought to be a prereq-
isite for cell differentiation [1,2], much attention has been paid
o the idea that CKI-led inhibition of G1-speciﬁc Cdks is critical for
ell differentiation. Hence, the potential roles of CKIs in differenti-
tion have been intensively studied, although these investigations
ave yielded mixed results. Many cell-based studies have revealed
 certain correlation between induction of p21CIP1 and/or P27KIP1
nd differentiation [7–10]. However, mice completely ableted for
21CIP1 and/or P27KIP1 or other major CKIs still develop normally
ith proper differentiation [11,12]. Although there is evidence for
57KIP2 being involved in the differentiation of some cells [13–16],
he cell cycle factors that are controlled by differentiation signals
nd critically inﬂuence the differentiation commitment process
ave not been identiﬁed. In lower eukaryotes, the control of the
ell cycle factors driving initiation of the S phase start greatly
nﬂuences the commitment to cell differentiation. Therefore, we
ecently investigated the possibility that certain cell cycle start fac-
ors participate in the control of mammalian cell differentiation and
iscovered that Cdk6, one of the cell cycle start factors, is a criti-
al regulator of the differentiation of osteoblasts, osteoclasts, and International 8 (2011) 2– 6 3
chondrocytes. In addition, individual groups have also reported the
importance of Cdk6 in the differentiation of multiple types of cells.
Based on these facts, we are on the verge of understanding the
molecular mechanisms of the differentiation control systems gov-
erned by Cdk6. In this article, we review the role of Cdk6 in the
differentiation of cells with a particular focus on osteoblast, osteo-
clast, and chondrocyte differentiation, and discuss its potential as
a target of bone regenerative medicine.
2. Cdk6 in osteoblast differentiation
Bone  morphogenetic protein (BMP)-2 is a potent inducer of
bone formation through its stimulation of osteoblast differentia-
tion [17]. To identify cell cycle factors that critically regulate early
differentiation, we analyzed the effect of BMP-2 on G1 cell cycle fac-
tors in the mouse osteoblastic cell line MC3T3-E1. The cells were
arrested in quiescence by serum starvation, and stimulated with
serum in the presence or absence of BMP-2. The amounts of cyclins
(D1, D2, D3, and E), Cdk2, Cdk4, Cdk6, CKIs (p18, p21, p27, and
p57) and Rb/phosphorylated-Rb proteins were analyzed by West-
ern blotting. In this cell line, the amounts of Cdk6, Cdk2, and p18
increased and the amount of p21 decreased during serum stim-
ulation, whereas the remaining factors were unchanged. When
the cells were stimulated with BMP-2, induction of Cdk6 com-
pletely disappeared, while the levels of the remaining factors were
indistinguishable from those obtained by serum stimulation. Since
Cdk6 downregulation by BMP-2 was also seen in a culture of
primary osteoblasts isolated from neonatal mouse calvariae, this
phenomenon is not speciﬁc to a particular cell line, but is con-
sidered to be more general. In addition to downregulation of the
protein, we  found that cdk6 mRNA disappeared when MC3T3-E1
cells were stimulated with BMP-2. Because Cdk6 and Cdk4 are sib-
lings and exert similar functions, and Cdk4 is known to be degraded
by the ubiquitin-proteasome system [18], we studied the involve-
ment of the same proteolytic system in the downregulation of Cdk6.
MG132, a potent inhibitor of this proteolytic system, did not affect
this downregulation of Cdk6, suggesting that the protein degra-
dation of Cdk6 was not involved with the ubiquitin-proteasome
system. These ﬁndings indicate that BMP-2 downregulated Cdk6
expression mainly by transcriptional repression. We investigated
the signal pathway involved in Cdk6 downregulation by BMP-
2. A differentiation signal transmitted by BMP-2 is known to be
mediated by Smad proteins, particularly by R-Smads (Smad1, 5,
8) and Co-Smads (Smad4), while I-Smads, such as Smad6 and
Smad7, inhibit this signaling [19]. When we  overexpressed Smad6
in MC3T3-E1 cells by using an adenovirus vector, downregulation
of Cdk6 by BMP-2 was completely cancelled. These data showed
that Smads mediated downregulation of Cdk6 by BMP-2. Next,
to determine whether downregulation of Cdk6 is essential for
osteoblast differentiation, we constructed MC3T3-E1 cell clones
stably expressing various levels of Cdk6 and compared differen-
tiation markers among control cells and low (∼2-fold) and high
(>10-fold) expressers. Induction of alkaline phosphatase (ALP) and
production of osteocalcin mRNA by BMP-2 treatment was inhib-
ited signiﬁcantly in the low and completely in the high expressers,
suggesting that downregulation of Cdk6 is essential for efﬁcient
osteoblast differentiation. Because Cdk6 promotes the G1–S tran-
sition, suppression of osteoblast differentiation by overexpressed
Cdk6 could be caused by the promotion of cell proliferation. There-
fore, we  evaluated the cell cycle distribution or the proliferation
rate of the cells determined by ﬂow cytometric analysis or bro-
modeoxyuridine (BrdU) uptake, respectively. Overexpression of
Cdk6 did not cause any signiﬁcant changes in either the cell cycle
distribution or the proliferation rate of the cells, implying that
the inhibitory effect of Cdk6 on osteoblast differentiation was not
4 ience International 8 (2011) 2– 6
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Fig. 2. Schematic presentation of the mechanism by which Cdk6 inhibits osteoblast,
osteoclast,  and chondrocyte differentiation. Differentiation signals such as BMP-2
(osteoblast), RANKL (osteoclast), or insulin (chondrocyte) are transmitted by signal-
ing pathways that are critical for cell differentiation (Smad for osteoblasts, NF-B for
osteoclasts, and p38 MAPK for chondrocytes). In response to differentiation stim-
ulation, downregulation of Cdk6 occurs and permits efﬁcient cell differentiation toT.  Ogasawara et al. / Oral Sc
xerted via cell cycle regulation. Finally, we investigated the asso-
iation between transcription factors and the inhibitory effect of
dk6, and the effects of this association on osteoblast differen-
iation. Rb, a repressor of the E2F-DP transcription factor, which
s essential for the S phase onset, has been reported to act as a
ranscriptional co-activator for Runx2, a key transcription factor
or osteoblast differentiation [20,21]. Because Rb is a direct tar-
et of Cdk6 in cell cycle control, we investigated the effects of
verexpression of Cdk6 on the in vivo binding of Runx2 and Rb
o the osteocalcin promoter during BMP-2 treatment. To this end,
e performed a chromatin immunoprecipitation (ChIP) assay and
ompared the binding of Runx2 and Rb to the osteocalcin promoter
mong the empty vector-transfected MC3T3-E1 cells and the low
nd high Cdk6 expressers at day 1 and day 4 post-BMP-2 treatment.
t day1, Runx2 was slightly bound to the osteocalcin promoter only
n the empty vector-transfected MC3T3-E1 cells, whereas no bind-
ng of Rb to this promoter was detected in any of these cells. At
ay 4, the binding of Runx2 to this promoter was clearly detected
n the empty vector-transfected MC3T3-E1 cells and the low Cdk6
xpresser, but not in the high Cdk6 expresser, in which osteoblast
ifferentiation was completely blocked. Thus, there was  a close
orrelation between osteoblast differentiation and the binding of
unx2 to the osteocalcin promoter in the Cdk6-induced inhibition
f differentiation. In contrast, there was no apparent correlation
etween Rb binding and the Cdk6-induced inhibition of differ-
ntiation, though Rb is certainly required for efﬁcient osteoblast
ifferentiation of MC3T3-E1 cells. At day 4, the binding of Rb to the
steocalcin promoter was  conﬁrmed in all these cells, as reported
reviously [21]. However, Rb seemed to bind the promoter inde-
endently of Runx2, because in the high Cdk6 expresser, Rb bound
he promoter without the binding of Runx2. The fact that the
unx2 binding to the osteocalcin promoter was  lost during the
dk6-induced differentiation inhibition raises the possibility that
dk6 may  inhibit osteoblastic differentiation by interfering with
he promoter-binding ability of the Runx2. These results indicate
hat Cdk6 is a critical regulator of BMP-2-induced osteoblast differ-
ntiation [22].
.  Cdk6 in osteoclast differentiation
The  receptor activator of the nuclear factor-B (NF-B) ligand
RANKL) is a tumor necrosis factor (TNF)-related cytokine that stim-
lates osteoclast differentiation from hematopoietic precursor cells
23–25]. Cells of the mouse osteoclast precursor cell line RAW, dif-
erentiate to osteoclasts in response to stimulation with RANKL. By
tudying this in vitro model, we investigated the involvement of cell
ycle factors that critically regulate osteoclast differentiation. We
hecked the protein expression levels of the G1 cell cycle factors,
yclins (D1, D2, D3, E), Cdk2, Cdk4, Cdk6, and Cdk inhibitors (p18
nd p27) in RAW cells cultured in the presence/absence of soluble
ANKL. The Cdk6 protein level was downregulated in RAW cells
ultured in the presence of RANKL. Inhibition of the NF-B path-
ay by the overexpression of dominant negative mutants of the IB
inase 2 (IKKDN) gene, using the adenovirus vectors [26], blocked
dk6 downregulation by RANKL. RAW cells constitutively overex-
ressing Cdk6 resisted RANKL-induced osteoclast differentiation as
etermined by tartrate-resistant acid phosphatase (TRACP) stain-
ng. On the other hand, overexpression of Cdk6 did not alter the
ell cycle regulation, as determined by BrdU uptake and ﬂow cyto-
etric analysis. The fact that the levels of Cdk6 overexpression did
ot change the cell cycle regulation suggested that the inhibitory
ffect of Cdk6 on osteoclast differentiation was  not caused by
romotion of proliferation. These results indicate that Cdk6 is a
ritical regulator of RANKL-induced osteoclast differentiation and
hat its NF-B-mediated downregulation is important for efﬁcient
steoclast differentiation [27]. However, there have been reportstake place.
Modiﬁed from Ref. [22].
indicating that the role of Cdk6 in osteoclast differentiation is highly
complex and diverse, and thus extensive studies will be needed
to precisely clarify the role of Cdk6 in osteoclast differentiation
[28,29].
4. Cdk6 in chondrocyte differentiation
Cells of the mouse prechondrocyte cell line ATDC5 differenti-
ate to chondrocytes in response to stimulation signals evoked by
insulin [30–32]. We  investigated the involvement of cell cycle fac-
tors in the differentiation process of chondrocytes by using ATDC5
cells. We  studied the amounts of cyclins (A, D1, D2, D3, and E),
Cdk2, Cdk4, Cdk6, and CKIs (p15, p16, p18, p19, p21, p27, and
p57) by Western blot analysis. Among these G1 cell cycle fac-
tors examined, both the protein and mRNA levels of Cdk6 were
suppressed in ATDC5 cells cultured with insulin. Since protea-
some inhibitors such as MG132 or lactacystin did not affect this
downregulation of Cdk6, the protein degradation of Cdk6 was  not
involved in this phenomenon. Insulin is known to initiate cellu-
lar responses by binding to distinct cell-surface receptor tyrosine
kinases which regulate diverse signaling pathways, such as those
of MAPK and PI3K/Akt [33]. In addition, in chondrogenic differen-
tiation, p38 MAPK, ERK-1/2, and PI3K/Akt [34–36], are reported to
play an important role. We  therefore investigated the involvement
of these signal pathways in the downregulation of Cdk6. Among
the inhibitors of p38 MAPK, ERK-1/2, and PI3K/Akt, only the p38
MAPK inhibitor SB203580 blocked the decrease in the Cdk6 pro-
tein level in cells cultured in the presence of insulin, indicating that
the Cdk6 suppression was  mediated by the p38 MAPK pathway.
The expressions of the chondrocyte marker of typeII collagen and
type X Collagen were markedly lower in ATDC5 cells constitutively
expressing Cdk6. Concerning the key transcription factors in chon-
drogenic differentiation, expressions of Sox5 and Sox6, but not Sox9
were suppressed in ATDC5 cells constitutively expressing Cdk6.
T. Ogasawara et al. / Oral Science International 8 (2011) 2– 6 5
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tig. 3. Regulation model of transcription factors controlled by Cdk6. Hypothetical 
heir transcriptional activities by competing with some transcriptional co-activator
ecreased  by differentiation stimulation, the levels of transcription factor and trans
ince Sox9 is essential for mesenchymal condensation that is pre-
equisite for the chondrogenic differentiation while Sox5 and Sox6
re needed thereafter as the co-activators, Cdk6 may  contribute to
he early stage of chondrogenic differentiation like commitment of
recursors to the lineage. However, the Cdk6 overexpression did
ot alter the cell cycle regulation, as determined by BrdU uptake
nd ﬂow cytometric analysis, suggesting that the inhibitory effect
f Cdk6 on the differentiation was exerted by a mechanism largely
ndependent of its cell cycle regulation. These results indicate that
dk6 may  regulate chondrocyte differentiation and that its p38-
ediated downregulation may  be involved in efﬁcient chondrocyte
ifferentiation [37].
.  Perspectives
.1. The role of Cdk6 in skeletogenesis and the molecular
echanism of osteoblast differentiation controlled by Cdk6
We  have found that Cdk6, a G1 cell cycle factor, plays a critical
ole in controlling osteoblast, osteoclast, and chondrocyte differ-
ntiation. A schematic presentation of the mechanism by which
dk6 inhibits osteoblast, osteoclast and chondrocyte differentia-
ion is shown in Fig. 2. It is worth noting that this ﬁnding is not
peciﬁc to the differentiation of these three cell types. Matushan-
ky et al. reported a similar role of Cdk6 in erythroid differentiation
f a murine leukemia cell line [38]. Fujimoto et al. reported that
ownregulation of Cdk6 is required for terminal granulocytic dif-
erentiation and that Cdk6 inhibits Runx1 activity by interfering
ith Runx1 DNA binding and Runx1-C/EBPalpha interaction [39].
ricson et al. reported that expression of Cdk6, but not Cdk4 alters
orphology of mouse astrocytes [40]. Slomiany et al. reported that
orced Cdk6 expression in mouse astrocytes results in changes in
he patterns of gene expression, changes in the actin cytoskeleton,
nd enhanced motility [41]. Kohrt et al. suggested that the subcellu-
ar distribution of Cdk6 is involved with this novel function of Cdk6
n differentiation [42]. Judging from these individual reports, it is
ertain that Cdk6 is one of the key regulators in the differentiation
f multiple types of cells, at least in cell-based studies. However,
s in the cases of p21CIP1-knockout mice [11] or P27KIP1-knockout
ice [12], Cdk6-knockout mice did not display gross anatomical
bnormalities [43], suggesting that the functions of Cdk6 can be
ompensated for in vivo by other cell cycle factors, possibly Cdk4
r Cdk2. With the purpose of uncovering the role of Cdk6 in skele-
ogenesis, we are now conducting a thorough investigation of the
keletal phenotype of Cdk6-knockout mice. In addition, we  are
rying to address the question of how Cdk6 controls osteoblast dif-
erentiation without inﬂuencing the cell cycle. One possibility is
hat Cdk6 directly controls a factor(s) critically involved in differen-e of Cdk6 function. Cdk6 binds to transcription factors such as Runx2 and inhibits
acts) in the undifferentiated cells. On the other hand, because Cdk6 expression was
onal co-activator complex increased and promoted the transcriptional activity.
tiation  as demonstrated in the previous works [39,44,45]. Because
the involvement of several transcription factors, such as Runx2,
osterix, and LDL receptor protein 5, have been reported in bone for-
mation [20,46,47], we  assume these factors might be responsible
for the BMP-2-invoked repression of Cdk6 transcription. In consid-
eration of all these previous results [39,44,45], including our own,
we propose a working hypothesis in regard to the regulatory mech-
anism of transcription factors controlled by Cdk6 (Fig. 3). However,
identiﬁcation of the transcriptional repressor as well as key targets
for Cdk6 will absolutely be required for a deeper understanding of
the molecular basis of cell differentiation.
5.2. Possibility of Cdk6 as a target of bone regenerative medicine
Finally,  we would like to discuss the possibility of Cdk6 as a tar-
get in bone regenerative medicine. In bone regenerative medicine,
BMPs have been clinically used for the treatment of long bone
non-unions and for spinal fusion [48–51]. However, as the effec-
tive doses of BMPs required in humans are much higher than those
used in smaller animals, the treatment requires a large amount of
expensive recombinant BMPs [51]. The problem of treatment cost
is one of the reasons why  this method has not been widely adopted.
Because downregulation of Cdk6 occurs downstream of BMP sig-
naling and is important for efﬁcient osteoblast differentiation, it is
natural to wonder whether Cdk6 might have potential as a target
of bone regenerative medicine. In order to address this question,
we are studying the effects of Cdk6 inhibition on osteoblasts by
overexpression of dominant negative (dn)Cdk6, silencing of Cdk6
through RNA interference or supplementation of Cdk6 inhibitors,
and we are preparing for in vivo study as well. For the time being, it
seems that Cdk6 could indeed be a candidate target in bone regen-
erative medicine (Ogasawara et al. unpublished data). Before long,
we will be able to report our ﬁnal conclusions, which we  hope will
contribute to bone regenerative medicine in the future.
Acknowledgments
We  thank Drs Hiroto Okayama, Hiroshi Kawaguchi, Toru Moro
and all our collaborators for their dedicated efforts and contri-
butions. This work was partly supported by a Grant-in-Aid for
Scientiﬁc Research from Japan Society for the Promotion of Science
(JSPS; No. 22659365 to T.O.).References
[1] Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551–5.
[2] Zhu L, Skoultchi AI. Coordinating cell proliferation and differentiation. Curr Opin
Genet Dev 2001;11:91–7.
6 ience I
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[50]  Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes
of anterior lumbar interbody fusion using recombinant human bone morpho-T.  Ogasawara et al. / Oral Sc
[3] Sherr CJ, Roberts JM.  CDK inhibitors: positive and negative regulators of G1-
phase progression. Genes Dev 1999;13:1501–12.
[4]  Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause.
Gene 2000;247:1–15.
[5] Meyerson M,  Enders GH, Wu CL, et al. A family of human cdc2-related protein
kinases. EMBO J 1992;11:2909–17.
[6] Meyerson M,  Harlow E. Identiﬁcation of G1 kinase activity for cdk6, a novel
cyclin D partner. Mol  Cell Biol 1994;14:2077–86.
[7]  Negishi Y, Ui N, Nakajima M,  et al. p21Cip-1/SDI-1/WAF-1 gene is involved
in chondrogenic differentiation of ATDC5 cells in vitro. J Biol Chem
2001;276:33249–56.
[8] Nakajima M,  Negishi Y, Tanaka H, et al. p21(Cip-1/SDI-1/WAF-1) expression
via the mitogen-activated protein kinase signaling pathway in insulin-induced
chondrogenic differentiation of ATDC5 cells. Biochem Biophys Res Commun
2004;320:1069–75.
[9] Muto A, Kizaki M,  Yamato K, et al. 1,25-Dihydroxyvitamin D3 induces differ-
entiation of a retinoic acid-resistant acute promyelocytic leukemia cell line
(UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood
1999;93:2225–33.
10] Okahashi N, Murase Y, Koseki T, et al. Osteoclast differentiation is asso-
ciated with transient upregulation of cyclin-dependent kinase inhibitors
p21(WAF1/CIP1) and p27(KIP1). J Cell Biochem 2001;80:339–45.
11] Deng C, Zhang P, Harper JW,  et al. Mice lacking p21CIP1/WAF1 undergo nor-
mal  development, but are defective in G1 checkpoint control. Cell 1995;82:
675–84.
12]  Nakayama K, Ishida N, Shirane M,  et al. Mice lacking p27(Kip1) display
increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary
tumors. Cell 1996;85:707–20.
13] Zhang P, Liegeois NJ, Wong C, et al. Altered cell differentiation and proliferation
in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome.
Nature 1997;387:151–8.
14] Yan Y, Frisen J, Lee MH,  et al. Ablation of the CDK inhibitor p57Kip2 results in
increased apoptosis and delayed differentiation during mouse development.
Genes Dev 1997;11:973–83.
15] Takahashi K, Nakayama K, Nakayama K. Mice lacking a CDK inhibitor,
p57Kip2,  exhibit skeletal abnormalities and growth retardation. J Biochem
2000;127:73–83.
16]  Stewart MC,  Kadlcek RM,  Robbins PD, et al. Expression and activity of the CDK
inhibitor p57Kip2 in chondrocytes undergoing hypertrophic differentiation. J
Bone Miner Res 2004;19:123–32.
17] Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and
regeneration. Nat Biotechnol 1998;16:247–52.
18]  Wang H, Goode T, Iakova P, et al. C/EBPalpha triggers proteasome-dependent
degradation  of cdk4 during growth arrest. EMBO J 2002;21:930–41.
19] Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta
signaling. Curr Opin Genet Dev 1998;8:103–11.
20]  Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a
complete lack of bone formation owing to maturational arrest of osteoblasts.
Cell 1997;89:755–64.
21]  Thomas DM,  Johnson SA, Sims NA, et al. Terminal osteoblast differentiation,
mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol
2004;167:925–34.
22] Ogasawara T, Kawaguchi H, Jinno S, et al. Bone morphogenetic protein 2-
induced osteoblast differentiation requires Smad-mediated down-regulation
of Cdk6. Mol  Cell Biol 2004;24:6560–8.
23] Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation
and function by the new members of the tumor necrosis factor receptor and
ligand families. Endocr Rev 1999;20:345–57.
24] Lacey DL, Timms  E, Tan HL, et al. Osteoprotegerin ligand is a cytokine
that  regulates osteoclast differentiation and activation. Cell 1998;93:
165–76.
25] Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a
ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical
to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597–602.
26]  Yamamoto A, Miyazaki T, Kadono Y, et al. Possible involvement of
IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by recep-
tor activator of nuclear factor kappaB ligand. J Bone Miner Res 2002;17:
612–21.
27] Ogasawara T, Katagiri M,  Yamamoto A, et al. Osteoclast differentiation by
RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent
kinase 6 (Cdk6). J Bone Miner Res 2004;19:1128–36.
[nternational 8 (2011) 2– 6
28] Mizoguchi T, Muto A, Udagawa N, et al. Identiﬁcation of cell cycle-arrested
quiescent osteoclast precursors in vivo. J Cell Biol 2009;184:541–54.
29] Meiyanto E, Hoshijima M,  Ogawa T, et al. Osteoclast differentiation factor mod-
ulates cell cycle machinery and causes a delay in s phase progression in RAW264
cells. Biochem Biophys Res Commun 2001;282:278–83.
30]  Shukunami C, Ishizeki K, Atsumi T, et al. Cellular hypertrophy and calciﬁcation
of embryonal carcinoma-derived chondrogenic cell line ATDC5 in vitro. J Bone
Miner Res 1997;12:1174–88.
31] Shukunami C, Ohta Y, Sakuda M,  et al. Sequential progression of the differen-
tiation program by bone morphogenetic protein-2 in chondrogenic cell line
ATDC5. Exp Cell Res 1998;241:1–11.
32] Shukunami C, Shigeno C, Atsumi T, et al. Chondrogenic differentiation of clonal
mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene
expression of parathyroid hormone (PTH)/PTH-related peptide receptor. J Cell
Biol 1996;133:457–68.
33] Kadowaki T, Tobe K, Honda-Yamamoto R, et al. Signal transduction mechanism
of insulin and insulin-like growth factor-1. Endocr J 1996;43 Suppl.:S33–41.
34] Seto H, Kamekura S, Miura T, et al. Distinct roles of Smad pathways and p38
pathways in cartilage-speciﬁc gene expression in synovial ﬁbroblasts. J Clin
Invest 2004;113:718–26.
35] Yonekura A, Osaki M,  Hirota Y, et al. Transforming growth factor-beta stim-
ulates articular chondrocyte cell growth through p44/42 MAP  kinase (ERK)
activation. Endocr J 1999;46:545–53.
36] Hidaka K, Kanematsu T, Takeuchi H, et al. Involvement of the phosphoinositide
3-kinase/protein kinase B signaling pathway in insulin/IGF-I-induced chon-
drogenesis of the mouse embryonal carcinoma-derived cell line ATDC5. Int J
Biochem Cell Biol 2001;33:1094–103.
37] Moro T, Ogasawara T, Chikuda H, et al. Inhibition of Cdk6 expression through
p38 MAP  kinase is involved in differentiation of mouse prechondrocyte ATDC5.
J Cell Physiol 2005;204:927–33.
38] Matushansky I, Radparvar F, Skoultchi AI. CDK6 blocks differentiation: coupling
cell proliferation to the block to differentiation in leukemic cells. Oncogene
2003;22:4143–9.
39]  Fujimoto T, Anderson K, Jacobsen SE, et al. Cdk6 blocks myeloid differentia-
tion by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction.
EMBO J 2007;26:2361–70.
40] Ericson KK, Krull D, Slomiany P, et al. Expression of cyclin-dependent kinase
6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse
astrocytes. Mol Cancer Res 2003;1:654–64.
41] Slomiany P, Baker T, Elliott ER, et al. Changes in motility, gene expression and
actin dynamics: Cdk6-induced cytoskeletal changes associated with differen-
tiation in mouse astrocytes. J Cell Biochem 2006;99:635–46.
42]  Kohrt DM,  Crary JI, Gocheva V, et al. Distinct subcellular distribution of cyclin
dependent kinase 6. Cell Cycle 2009;8:2837–43.
43] Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without
the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118:493–504.
44] Nerlov C. The C/EBP family of transcription factors: a paradigm for inter-
action between gene expression and proliferation control. Trends Cell Biol
2007;17:318–24.
45]  Grossel MJ,  Hinds PW.  Beyond the cell cycle: a new role for Cdk6 in differenti-
ation. J Cell Biochem 2006;97:485–93.
46] Nakashima K, Zhou X, Kunkel G, et al. The novel zinc ﬁnger-containing tran-
scription factor osterix is required for osteoblast differentiation and bone
formation. Cell 2002;108:17–29.
47] Patel MS, Karsenty G. Regulation of bone formation and vision by LRP5. N Engl
J Med 2002;346:1572–4.
48] Govender S, Csimma C, Genant HK, et al. Recombinant human bone mor-
phogenetic protein-2 for treatment of open tibial fractures: a prospective,
controlled, randomized study of four hundred and ﬁfty patients. J Bone Joint
Surg Am 2002;84-A:2123–34.
49] Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morpho-
genetic protein-2 to achieve posterolateral lumbar spine fusion in humans:
a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical
studies. Spine (Phila Pa 1976) 2002;27:2662–73.genetic protein-2. Spine (Phila Pa 1976) 2002;27:2396–408.
51]  Bishop GB, Einhorn TA. Current and future clinical applications of bone mor-
phogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007;31:721–7.
